Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$12.92
+7.7%
$11.78
$4.88
$19.58
$280.36MN/A93,112 shs8,000 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.04
-1.4%
$4.55
$2.76
$6.00
$237.54M0.4111,266 shs241 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$3.01
+1.0%
$3.03
$1.10
$6.01
$51.70M1.59422,119 shs18,356 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$25.00
-3.4%
$25.71
$8.13
$34.31
$234M0.234,620 shs7,048 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
+3.27%-0.91%+7.82%+56.66%+1,199,999,900.00%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-2.85%-0.78%+14.32%+51.63%-5.37%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
+1.36%-7.17%-8.59%+56.02%+27.90%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
+5.16%-13.24%+0.43%+2,587,999,900.00%+2,587,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
1.9167 of 5 stars
3.35.00.00.00.00.00.6
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.3419 of 5 stars
3.64.00.00.00.60.80.6
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3.00
Buy$33.00155.42% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0058.73% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.20
Buy$28.50847.16% Upside
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.00
Buy$64.25157.00% Upside

Current Analyst Ratings Breakdown

Latest NRXP, AARD, NBTX, and TVRD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$62.00
7/11/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$52.00
6/30/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
6/20/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/12/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$78.00
6/6/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
5/21/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/16/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
5/15/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/30/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/29/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.06N/AN/A($1.51) per share-3.34
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/A($1.48) per shareN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M32.77N/AN/A($3.02) per share-8.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$20.59MN/A0.00N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$70.87MN/A0.00N/A-595.39%-710.04%-79.00%N/A

Latest NRXP, AARD, NBTX, and TVRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.31N/AN/AN/AN/AN/A
5/15/2025Q1 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million
5/14/2025N/A
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$0.70-$0.71-$0.01-$0.71N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
25.86
25.86
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.22
0.22
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
32.48
31.73

Institutional Ownership

CompanyInstitutional Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%

Insider Ownership

CompanyInsider Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
19.00%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
1821.70 millionN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
217.29 million14.00 millionOptionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
809.36 million9.07 millionN/A

Recent News About These Companies

Cantor Fitzgerald Predicts TVRD FY2025 Earnings
TVRD Tvardi Therapeutics, Inc.
Tvardi Therapeutics Inc (TVRD)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aardvark Therapeutics stock logo

Aardvark Therapeutics NASDAQ:AARD

$12.92 +0.92 (+7.67%)
As of 10:16 AM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.04 -0.07 (-1.37%)
As of 10:31 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$3.01 +0.03 (+0.97%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$25.00 -0.88 (-3.40%)
As of 10:12 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.